Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1745-8315.2010.00275.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.
Pharmaceuticals (Basel)
October 2024
Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients' quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis.
View Article and Find Full Text PDFPolypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry.
J Antimicrob Chemother
September 2024
Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy.
Objectives: To evaluate polypharmacy, anticholinergic burden (ACB) and drug-drug interactions (DDIs) in people with four-class-resistant HIV (4DR-PWH).
Methods: We performed a cross-sectional study, including 4DR-PWH from the PRESTIGIO Registry taking at least one non-antiretroviral drug. Polypharmacy was defined as taking five or more non-antiretroviral drugs.
Comparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial).
Trials
July 2024
Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Article Synopsis
- This study investigates the effectiveness of two surfactant administration methods—INtubate-RECruit-SURfactant-Extubate (IN-REC-SUR-E) and less invasive surfactant administration (LISA)—on improving BPD-free survival in preterm infants with respiratory distress syndrome (RDS).
- A total of 382 preterm infants, born at 24-27 weeks' gestation and not intubated at birth, will be randomly assigned to either method within the first 24 hours of life. The primary outcome being measured is a combination of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age.
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial.
Lancet Haematol
July 2024
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. Electronic address:
Article Synopsis
- This study looked at treating early-stage follicular lymphoma with radiation therapy and a medicine called ofatumumab.
- They treated patients first with radiation and then gave ofatumumab to those still having cancer traces in their blood.
- Out of the 110 people in the study, many improved after treatment, with some showing no signs of the disease for a long time.
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study.
J Eur Acad Dermatol Venereol
June 2024
Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy.
Background: Facial (FP) and genital psoriasis (GP) significantly affect patients' quality of life. Despite the advances in treatments, limited data on efficacy and safety are available on these difficult-to-treat areas. Guselkumab is an interleukin (IL)-23 inhibitor which has been proven effective in treating patients with moderate-to-severe plaque psoriasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!